| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Dermatology, University of Erlangen-Nuremberg, Erlangen, Germany;
Department of Dermatology, University of Wurzburg, Wurzburg, Germany;
Department of Dermatology, University of Mainz, Mainz, Germany;
§
Molecular Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
Dendritic cell (DC) vaccination, albeit still in an early stage, is
a promising strategy to induce immunity to cancer. We explored whether
DC can expand Ag-specific CD8+ T cells even in far-advanced
stage IV melanoma patients. We found that three to five biweekly
vaccinations of mature, monocyte-derived DC (three vaccinations of
6 x 106 s.c. followed by two i.v. ones of 6 and
12 x 106, respectively) pulsed with Mage-3A2.1 tumor
and influenza matrix A2.1-positive control peptides as well as the
recall Ag tetanus toxoid (in three of eight patients) generated in all
eight patients Ag-specific effector CD8+ T cells that were
detectable in blood directly ex vivo. This is the first time that
active, melanoma peptide-specific, IFN-
-producing, effector
CD8+ T cells have been reliably observed in patients
vaccinated with melanoma Ags. Therefore, our DC vaccination strategy
performs an adjuvant role and encourages further optimization of this
new immunization approach.
This article has been cited by other articles:
|
|
 |
|
  C Bauer, F Bauernfeind, A Sterzik, M Orban, M Schnurr, H A Lehr, S Endres, A Eigler, and M Dauer Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut, September 1, 2007; 56(9): 1275 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parra-Lopez, J. M. Calvo-Calle, T. O. Cameron, L. E. Vargas, L. M. Salazar, M. E. Patarroyo, E. Nardin, and L. J. Stern Major Histocompatibility Complex and T Cell Interactions of a Universal T Cell Epitope from Plasmodium falciparum Circumsporozoite Protein J. Biol. Chem., May 26, 2006; 281(21): 14907 - 14917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Breckpot, J. Corthals, A. Bonehill, A. Michiels, S. Tuyaerts, C. Aerts, C. Heirman, and K. Thielemans Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response J. Leukoc. Biol., October 1, 2005; 78(4): 898 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, Z. Sun, H. Nicolay, R. G. Meyer, N. Renkvist, V. Stroobant, J. Corthals, J. Carrasco, A. M. M. Eggermont, M. Marchand, et al. Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein J. Immunol., February 15, 2005; 174(4): 2404 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sakai, B. J. Morrison, J. D. Burke, J.-M. Park, M. Terabe, J. E. Janik, G. Forni, J. A. Berzofsky, and J. C. Morris Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice Cancer Res., November 1, 2004; 64(21): 8022 - 8028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lou, G. Wang, G. Lizee, G. J. Kim, S. E. Finkelstein, C. Feng, N. P. Restifo, and P. Hwu Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo Cancer Res., September 15, 2004; 64(18): 6783 - 6790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ratzinger, J. Baggers, M. A. de Cos, J. Yuan, T. Dao, J. L. Reagan, C. Munz, G. Heller, and J. W. Young Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells J. Immunol., August 15, 2004; 173(4): 2780 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rouas, P. Lewalle, F. El Ouriaghli, B. Nowak, H. Duvillier, and P. Martiat Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12 Int. Immunol., May 1, 2004; 16(5): 767 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schultz, B. Schuler-Thurner, V. Stroobant, L. Jenne, T. G. Berger, K. Thielemanns, P. van der Bruggen, and G. Schuler Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy J. Immunol., January 15, 2004; 172(2): 1304 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Butterfield, A. Ribas, W. S. Meng, V. B. Dissette, S. Amarnani, H. T. Vu, E. Seja, K. Todd, J. A. Glaspy, W. H. McBride, et al. T-Cell Responses to HLA-A*0201 Immunodominant Peptides Derived from {alpha}-Fetoprotein in Patients with Hepatocellular Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5902 - 5908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Goldszmid, J. Idoyaga, A. I. Bravo, R. Steinman, J. Mordoh, and R. Wainstok Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma J. Immunol., December 1, 2003; 171(11): 5940 - 5947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Wissniowski, J. Hansler, D. Neureiter, M. Frieser, S. Schaber, B. Esslinger, R. Voll, D. Strobel, E. G. Hahn, and D. Schuppan Activation of Tumor-specific T Lymphocytes by Radio-Frequency Ablation of the VX2 Hepatoma in Rabbits Cancer Res., October 1, 2003; 63(19): 6496 - 6500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakahara, T. Tsunoda, T. Baba, S. Asabe, and H. Tahara Dendritic Cells Stimulated with a Bacterial Product, OK-432, Efficiently Induce Cytotoxic T Lymphocytes Specific to Tumor Rejection Peptide Cancer Res., July 15, 2003; 63(14): 4112 - 4118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tschoep, T. C. Manning, H. Harlin, C. George, M. Johnson, and T. F. Gajewski Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines J. Leukoc. Biol., July 1, 2003; 74(1): 69 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, P. Chaux, V. Stroobant, A. M. M. Eggermont, J. Corthals, B. Maillere, K. Thielemans, M. Marchand, T. Boon, and P. van der Bruggen A MAGE-3 Peptide Presented by HLA-DR1 to CD4+ T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein J. Immunol., July 1, 2003; 171(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ng-Cashin, J. J. Kuhns, S. E. Burkett, J. D. Powderly, R. R. Craven, H. W. van Deventer, S. L. Kirby, and J. S. Serody Host Absence of CCR5 Potentiates Dendritic Cell Vaccination J. Immunol., April 15, 2003; 170(8): 4201 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients J. Immunol., February 15, 2003; 170(4): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Davis, M. Jefford, P. Parente, and J. Cebon Rational approaches to human cancer immunotherapy J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Luft, M. Jefford, P. Luetjens, T. Toy, H. Hochrein, K.-A. Masterman, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets Blood, July 30, 2002; 100(4): 1362 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schuler-Thurner, E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, et al. Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells J. Exp. Med., May 20, 2002; 195(10): 1279 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Prabakaran, C. Menon, S. Xu, A. Gomez-Yafal, B. J. Czerniecki, and D. L. Fraker Mature CD83+ Dendritic Cells Infected With Recombinant gp100 Vaccinia Virus Stimulate Potent Antimelanoma T Cells Ann. Surg. Oncol., May 1, 2002; 9(4): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Palmowski, E. M.-L. Choi, I. F. Hermans, S. C. Gilbert, J.-L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, E. Bonin, et al. Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols J. Immunol., May 1, 2002; 168(9): 4391 - 4398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Buelens, E. J. Bartholome, Z. Amraoui, M. Boutriaux, I. Salmon, K. Thielemans, F. Willems, and M. Goldman Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties Blood, February 1, 2002; 99(3): 993 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kufer, A. Zippelius, R. Lutterbuse, I. Mecklenburg, T. Enzmann, A. Montag, D. Weckermann, B. Passlick, N. Prang, P. Reichardt, et al. Heterogeneous Expression of MAGE-A Genes in Occult Disseminated Tumor Cells: A Novel Multimarker Reverse Transcription-Polymerase Chain Reaction for Diagnosis of Micrometastatic Disease Cancer Res., January 1, 2002; 62(1): 251 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ponnazhagan, G. Mahendra, D. T. Curiel, and D. R. Shaw Adeno-Associated Virus Type 2-Mediated Transduction of Human Monocyte-Derived Dendritic Cells: Implications for Ex Vivo Immunotherapy J. Virol., October 1, 2001; 75(19): 9493 - 9501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Banchereau, A. K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K. M. Wittkowski, N. Bhardwaj, et al. Immune and Clinical Responses in Patients with Metastatic Melanoma to CD34+ Progenitor-derived Dendritic Cell Vaccine Cancer Res., September 1, 2001; 61(17): 6451 - 6458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Salio, D. Shepherd, P. R. Dunbar, M. Palmowski, K. Murphy, L. Wu, and V. Cerundolo Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC J. Immunol., August 1, 2001; 167(3): 1188 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, Y. Song, D. S. B. Hoon, E. Appella, and E. Celis Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles Cancer Res., June 1, 2001; 61(12): 4773 - 4778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ebner, G. Ratzinger, B. Krosbacher, M. Schmuth, A. Weiss, D. Reider, R. A. Kroczek, M. Herold, C. Heufler, P. Fritsch, et al. Production of IL-12 by Human Monocyte-Derived Dendritic Cells Is Optimal When the Stimulus Is Given at the Onset of Maturation, and Is Further Enhanced by IL-4 J. Immunol., January 1, 2001; 166(1): 633 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Baggers, G. Ratzinger, and J. W. Young Dendritic Cells as Immunologic Adjuvants for the Treatment of Cancer J. Clin. Oncol., December 1, 2000; 18(23): 3879 - 3882. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
